Language

English

Publication Date

10-1-2023

Journal

Kidney International

DOI

10.1016/j.kint.2023.05.009

PMID

37236424

Abstract

Anemia is common in patients with chronic kidney disease and is associated with a high burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline for the diagnosis and management of anemia in chronic kidney disease. Since then, new data from studies assessing established and emerging therapies for the treatment of anemia and iron deficiency have become available. Beginning in 2019, KDIGO planned 2 Controversies Conferences to review the new evidence and its potential impact on the management of anemia in clinical practice. Here, we report on the second of these conferences held virtually in December 2021, which focused on a new class of agents-the hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs). This report provides a review of the consensus points and controversies from this second conference and highlights areas that warrant prioritization for future research.

Keywords

Humans, Anemia, Renal Insufficiency, Chronic, Hypoxia-Inducible Factor-Proline Dioxygenases, Prolyl Hydroxylases, Prolyl-Hydroxylase Inhibitors, anemia, chronic kidney disease, dialysis, erythropoiesis-stimulating agents, hypoxia-inducible factor-prolyl hydroxylase inhibitors, major adverse cardiovascular events

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.